Similarly, in the CASPIAN study, durvalumab, also a PD-L1 inhibitor, in combination with etoposide and cisplatin or carboplatin significantly improved OS in comparison to etoposide with cisplatin or carboplatin in patients with previously untreated ES-SCLC (10). The gene discussed is CD274; the disease is small cell lung carcinoma.